Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Current Deferred Revenue (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Current Deferred Revenue for 3 consecutive years, with $27.2 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 37.78% to $27.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.2 million through Dec 2025, up 37.78% year-over-year, with the annual reading at $27.2 million for FY2025, 37.78% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $27.2 million at Phathom Pharmaceuticals, up from $24.3 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $27.2 million in Q4 2025, with the low at $276000.0 in Q2 2023.
  • Average Current Deferred Revenue over 3 years is $15.1 million, with a median of $17.3 million recorded in 2025.
  • The sharpest move saw Current Deferred Revenue surged 3490.58% in 2024, then rose 4.79% in 2025.
  • Over 3 years, Current Deferred Revenue stood at $7.1 million in 2023, then soared by 178.12% to $19.8 million in 2024, then skyrocketed by 37.78% to $27.2 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $27.2 million, $24.3 million, and $21.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.